These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 17716353

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
    Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK.
    Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
    Lacey LF, Gane E.
    J Viral Hepat; 2007 Nov; 14(11):751-66. PubMed ID: 17927611
    [Abstract] [Full Text] [Related]

  • 7. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.
    Takeda A, Jones J, Shepherd J, Davidson P, Price A.
    J Viral Hepat; 2007 Feb; 14(2):75-88. PubMed ID: 17244247
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J.
    Pharmacoeconomics; 2004 Feb; 22(4):257-65. PubMed ID: 14974875
    [Abstract] [Full Text] [Related]

  • 10. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.
    N Engl J Med; 2005 Jun 30; 352(26):2682-95. PubMed ID: 15987917
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland.
    Orlewska E.
    Value Health; 2002 Jun 30; 5(5):405-21. PubMed ID: 12201858
    [Abstract] [Full Text] [Related]

  • 15. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.
    Crowley S, Tognarini D, Desmond P, Lees M, Saal G.
    J Gastroenterol Hepatol; 2002 Feb 30; 17(2):153-64. PubMed ID: 11966945
    [Abstract] [Full Text] [Related]

  • 16. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG, Lau DT, Schmid P, Perrillo R.
    Am J Gastroenterol; 2007 Dec 30; 102(12):2718-23. PubMed ID: 17662102
    [Abstract] [Full Text] [Related]

  • 17. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
    Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P, Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.
    Gut; 2007 May 30; 56(5):699-705. PubMed ID: 17127704
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Wu B, Li T, Chen H, Shen J.
    Value Health; 2010 Aug 30; 13(5):592-600. PubMed ID: 20561341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.